HomeCompareSQZ vs ADC

SQZ vs ADC: Dividend Comparison 2026

SQZ yields 459.77% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SQZ wins by $32296.65M in total portfolio value
10 years
SQZ
SQZ
● Live price
459.77%
Share price
$0.44
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32296.82M
Annual income
$22,619,113,625.24
Full SQZ calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — SQZ vs ADC

📍 SQZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSQZADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SQZ + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SQZ pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SQZ
Annual income on $10K today (after 15% tax)
$39,080.46/yr
After 10yr DRIP, annual income (after tax)
$19,226,246,581.45/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, SQZ beats the other by $19,226,178,881.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SQZ + ADC for your $10,000?

SQZ: 50%ADC: 50%
100% ADC50/50100% SQZ
Portfolio after 10yr
$16148.50M
Annual income
$11,309,596,636.24/yr
Blended yield
70.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

SQZ
Analyst Ratings
4
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$4.00
+819.5% upside vs current
Range: $4.00 — $4.00
Altman Z
-22.9
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SQZ buys
0
ADC buys
0
No recent congressional trades found for SQZ or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSQZADC
Forward yield459.77%4.11%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$32296.82M$176.9K
Annual income after 10y$22,619,113,625.24$79,647.25
Total dividends collected$31438.26M$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$4.00$81.06

Year-by-year: SQZ vs ADC ($10,000, DRIP)

YearSQZ PortfolioSQZ Income/yrADC PortfolioADC Income/yrGap
1← crossover$56,677$45,977.01$10,987$577.21+$45.7KSQZ
2$304,181$243,536.41$12,293$855.34+$291.9KSQZ
3$1,547,006$1,221,532.43$14,088$1,290.70+$1.53MSQZ
4$7,461,354$5,806,058.08$16,660$1,994.91+$7.44MSQZ
5$34,154,829$26,171,179.52$20,525$3,181.85+$34.13MSQZ
6$148,508,521$111,962,854.47$26,654$5,286.90+$148.48MSQZ
7$613,881,121$454,977,003.60$37,006$9,259.47+$613.84MSQZ
8$2,414,527,788$1,757,674,987.75$55,862$17,338.74+$2414.47MSQZ
9$9,044,589,126$6,461,044,393.43$93,452$35,300.32+$9044.50MSQZ
10$32,296,823,990$22,619,113,625.24$176,931$79,647.25+$32296.65MSQZ

SQZ vs ADC: Complete Analysis 2026

SQZStock

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Full SQZ Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this SQZ vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SQZ vs SCHDSQZ vs JEPISQZ vs OSQZ vs KOSQZ vs MAINSQZ vs NNNSQZ vs EPRTSQZ vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.